Patterns of serotonergic antidepressant usage in prodromal Huntington disease

Psychiatry Res. 2012 Apr 30;196(2-3):309-14. doi: 10.1016/j.psychres.2011.09.005. Epub 2012 Mar 5.

Abstract

Antidepressant usage in prodromal Huntington Disease (HD) remains uncharacterized, despite its relevance in designing experiments, studying outcomes of HD, and evaluating the efficacy of therapeutic interventions. We searched baseline medication logs of 787 prodromal HD and 215 healthy comparison (HC) participants for antidepressant use. Descriptive and mixed-effects logistic regression modeling characterized usage across participants. At baseline, approximately one in five prodromal HD participants took antidepressants. Of those, the vast majority took serotonergic antidepressants (selective serotonin reuptake inhibitor (SSRI) or serotonin/norepinephrine reuptake inhibitor (SNRI)). Significantly more prodromal HD participants used serotonergic antidepressants than their HC counterparts. Because of the prevalence of these medications, further analyses focused on this group alone. Mixed-effects logistic regression modeling revealed significant relationships of both closer proximity to diagnosis and female sex with greater likelihood to be prescribed a serotonergic antidepressant. More prodromal HD participants took antidepressants in general and specifically the subclass of serotonergic antidepressants than their at-risk counterparts, particularly when they were closer to predicted time of conversion to manifest HD. These propensities must be considered in studies of prodromal HD participants.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Antidepressive Agents / therapeutic use*
  • Cohort Studies
  • Female
  • Humans
  • Huntington Disease / complications
  • Huntington Disease / drug therapy*
  • Logistic Models
  • Male
  • Middle Aged
  • Movement Disorders / drug therapy
  • Movement Disorders / etiology
  • Psychiatric Status Rating Scales
  • Retrospective Studies
  • Serotonin Uptake Inhibitors / pharmacology*
  • Severity of Illness Index
  • Sex Factors

Substances

  • Antidepressive Agents
  • Serotonin Uptake Inhibitors